<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643056</url>
  </required_header>
  <id_info>
    <org_study_id>S10PANI01</org_study_id>
    <nct_id>NCT02643056</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer</brief_title>
  <acronym>S10PANI01</acronym>
  <official_title>Phase II Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Europe New Drug Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Unit Ente Ospedaliero Cantonale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Europe New Drug Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, multicenter, open labelled, uncontrolled study to evaluate the efficacy and safety&#xD;
      profile of panitumumab in patients affected by Head and Neck cancer after at least one&#xD;
      cisplatin or carboplatin-based chemotherapy. A translational research study is also planned&#xD;
      to evaluate Estimated Glomerular Filtration Rate (EGFR) status by FISH, KRAS, B-RAF, HRAS,&#xD;
      NRAS and PIK3CA mutation by DNA sequencing, PTEN protein expression by immunohistochemistry,&#xD;
      and Human Papilloma Virus (HPV) genotyping by reverse hybridization.&#xD;
&#xD;
      Panitumumab is administered iv on days 1 and 15 of a 28 days cycle, until progressive&#xD;
      disease, unacceptable toxicity, pregnancy, or patient's refusal&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of tumor response in advanced platinum-resistant head and neck cancer</measure>
    <time_frame>Radiological tumor evaluation every 8 weeks, minimum 12 weeks</time_frame>
    <description>To evaluate rate of radiological tumor response in advanced platinum-resistant head and neck cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event according to Common Terminology Criteria for Adverse Events (CTCAE) v.3</measure>
    <time_frame>Collection of adverse event for at least the first 8 weeks</time_frame>
    <description>To collect all adverse event occurred during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of tumor biomarkers</measure>
    <time_frame>28 days (1 cycle)</time_frame>
    <description>To identify the tumor biomarkers that can best predict response to panitumumab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Advanced Head and Neck Squamous Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg per administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>IV administration every 2 weeks</description>
    <arm_group_label>Panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2, not pregnant.&#xD;
&#xD;
          -  Histologically or cytologically confirmed Squamous Cell Cancer of the Head and Neck&#xD;
             either metastatic or recurrent, judged incurable by surgery or radiation.&#xD;
&#xD;
          -  Baseline tumor tissue, sufficient material available for EGFR determination&#xD;
             (therapeutic target of panitumumab) and biomarker studies. Patients without available&#xD;
             tissue at baseline or with tissue collected longer than 1 year before, may undergo&#xD;
             tumor biopsy.&#xD;
&#xD;
          -  Progression after or not responding to treatment with at least one cis-platin or&#xD;
             carboplatin containing regimen.&#xD;
&#xD;
          -  Measurable disease (Response Evaluation Criteria in Solid Tumours - RECIST 1.1).&#xD;
&#xD;
          -  Adequate hematological values, renal and hepatic function.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Platinum-na√Øve patients.&#xD;
&#xD;
          -  Patients previously progressed after a regimen containing EGFR-inhibiting agents (as&#xD;
             cetuximab, panitumumab, gefitinib, erlotinib), even if there was an initial response.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) 1 year before enrollment/randomization.&#xD;
&#xD;
          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest computed tomography scan.&#xD;
&#xD;
          -  Known or suspected brain metastases.&#xD;
&#xD;
          -  Psychiatric disorder precluding understanding of information on trial related topics,&#xD;
             giving informed consent&#xD;
&#xD;
          -  Known hypersensitivity to panitumumab active ingredient or excipients.&#xD;
&#xD;
          -  Any concomitant drugs contraindicated for use with the trial drug according to the&#xD;
             Swissmedic approved product information - Human Immunodeficiency Virus (HIV) positive&#xD;
             patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Ghielmini, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Oncology Institute of Southern Switzerland</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Institute of Southern Switzerland</investigator_affiliation>
    <investigator_full_name>Tatiana Terrot</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

